Yael L. Maxwell

The single-arm INVEST-CTO study showed high procedural success with a two-part intervention, but questions remain.

The real-world Evoque and new TRILUMINATE findings provide an “extension” from the pivotal trials, Dharam Kumbhani says.

More work needs to be done to tease out the mechanisms by which GLP-1 RAs lower the risk of MACE, researchers say.

Given that polygenic risk doesn’t change and only needs to be measured once, researchers advocate greater use.

Researchers support limiting these surgeries to centers that do the most cases, though true high-volume hospitals remain rare.

Doctors might feel out of their element making the videos, but patients respond to the short, informative reels.

The findings sparked a debate about the merits of RCTs vs other study designs—one surgeon urged others to “read a textbook.”

Despite success in some cancer patients, a drug that neutralizes GDF-15 was clearly harmful in HF patients. The question is, why?

Vocal monitoring has the potential to identify HF patients with worsening congestion early and prevent acute decompensation.

The Integra-D trial shows the device, which provides cardiac contractility modulation and defibrillation, also eases symptoms.